SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY

Previous results of the ongoing single-arm, phase 2 LITESPARK-004 (NCT03401788) study showed clinically meaningful antitumor activity with the HIF-2α inhibitor belzutifan for von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), CNS hemangioblastomas, and other neoplasms. Adults wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Narayan, Vivek, Iliopoulos, Othon, Iversen, Ane B, Maughan, Benjamin L, Beckermann, Kathryn E, Oudard, Stephane, Else, Tobias, Maranchie, Jodi K, Fu, Wei, Perini, Rodolfo F, Liu, Yanfang, Linehan, W Marston, Srinivasan, Ramaprasad, Jonasch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Systemic Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402338/
http://dx.doi.org/10.1093/noajnl/vdad070.122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402338/
http://dx.doi.org/10.1093/noajnl/vdad070.122

Ejemplares similares